DJIA 16,351.38 293.03 1.82%
NASDAQ 4,749.98 113.87 2.46%
S&P 500 1,948.86 35.01 1.83%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)



company name or ticker

Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MO

Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market

Market Panic Has Created 'Compelling' Opportunities In Biotech

Relative Strength Alert For Nektar Therapeutics

Nektar Q2 Loss Wider-than-Expected, Outlook Maintained - Analyst Blog

Nektar Therapeutics' (NKTR) CEO Howard Robin on Q2 2015 Results - Earnings Call Transcript

Nektar Therapeutics (NKTR) Q2 2015 Results - Earnings Call Webcast

FBT, AMGN, TECH, NKTR: ETF Inflow Alert

Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog

Huge Biotech Index Rebalance Means Massive Buy Orders for 5 Stocks

Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention

Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A
See More Articles...